GH Research (GHRS)
NASDAQ: GHRS
· Real-Time Price · USD
13.82
-0.68 (-4.69%)
At close: Oct 16, 2025, 3:59 PM
13.82
0.00%
After-hours: Oct 16, 2025, 04:10 PM EDT
-4.69% (1D)
| Bid | 13.5 |
| Market Cap | 857.24M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -41.02M |
| EPS (ttm) | -0.73 |
| PE Ratio (ttm) | -18.93 |
| Forward PE | -8.02 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 16.27 |
| Volume | 307,763 |
| Avg. Volume (20D) | 315,278 |
| Open | 14.50 |
| Previous Close | 14.50 |
| Day's Range | 13.59 - 14.87 |
| 52-Week Range | 6.72 - 20.50 |
| Beta | 0.98 |
| Ex-Dividend Date | n/a |
About GHRS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol GHRS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for GHRS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+0.76%
Shares of psychedelic companies are trading higher...
Unlock content with
Pro Subscription
2 months ago
+10.98%
Shares of psychedelic companies are trading higher following a report suggesting California Governor Newsom said he is "all in" on expanding access to psychedelics for therapeutic use.
2 months ago · proactiveinvestors.com
atai Life Sciences poised to lead treatment-resistant depression market with psychedelic candidateatai Life Sciences (NASDAQ:ATAI, ETR:9VC) is gaining momentum in the psychedelics space, with Jefferies analysts highlighting the company's potential to leapfrog rival GH Research (NASDAQ:GHRS) and es...
2 months ago · proactiveinvestors.co.uk
atai Life Sciences poised to lead treatment-resistant depression market with psychedelic candidate BPL-003atai Life Sciences (NASDAQ:ATAI, ETR:9VC) is gaining momentum in the psychedelics space, with Jefferies analysts highlighting the company's potential to leapfrog rival GH Research (NASDAQ:GHRS) and es...
